OSE Immunotherapeutics Advances Immunotherapy: Tedopi & OSE‑279 Hit Key Trials
Explore OSE Immunotherapeutics’ breakthrough immunotherapies—from phase‑III lung cancer trials to innovative ulcerative colitis treatments—shaping future oncology and inflammation care.
2 minutes to read

